Cost-Utility Analysis Of Alemtuzumab Versus Natalizumab For The Treatment Of Relapsing-Remitting Multiple Sclerosis- Us Payer Perspective
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.490
https://www.valueinhealthjournal.com/article/S1098-3015(16)31857-5/fulltext
Title :
Cost-Utility Analysis Of Alemtuzumab Versus Natalizumab For The Treatment Of Relapsing-Remitting Multiple Sclerosis- Us Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31857-5&doi=10.1016/j.jval.2016.09.490
First page :
A431
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
462